Clinical evaluation on the long-term use of halometasone ointment in chronic eczema and psoriasis.

This clinical evaluation to determine the long-term therapeutic efficacy and tolerability of 0.05% halometasone ointment was carried out in fifty patients (forty-one with psoriasis and nine with chronic eczema) by seven dermatologists in Austria and Switzerland. The ages ranged from 19 to 76 years and the total duration of illness was more than 5 years in 62% of the trial population. The duration of treatment varied from 38 to 103 days (38-60 days in twenty-two patients, 61-90 days in twenty-five patients and 91-103 days in three patients). All patients received two non-occlusive applications of halometasone ointment per day. In this long-term study halometasone ointment exhibited very satisfactory therapeutic efficacy and very good tolerability. 'Good' to 'very good' results were reported in 73% and 89% of the patients with psoriasis and chronic eczema treated with halometasone ointment, respectively. Adverse effects were reported in only two (4%) patients who had transient itching at the site of application. Neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed in this study, nor were any instances of contact skin allergy reported.

A comparative multicentre trial of halometasone/triclosan cream and betamethasone dipropionate/gentamicin sulphate cream in the treatment of infected acute eczematous dermatitis.

A multicentre, between-patient, comparative trial was carried out to compare the efficacy and tolerability of a cream containing 0.05 halometasone and 1% triclosan with those of a cream with 0.05% betametasone dipropionate and 0.1% gentamicin sulphate in patients suffering from infected acute ezcematous dermatoses. In the evaluable trial population, consisting of 265 patients, halometasone/triclosan cream yielded a significantly (p = 0.001) higher success rate ('good' to 'very good' results), namely 96%, than the comparative cream (80%). Halometasone/triclosan cream also displayed a significantly (p = 0.008) higher cure rate (73.9%) than that observed with the comparative preparation (58.6%). The proportion of patients obtaining an early cure, i.e. in less than 20 days, was significantly (p = 0.0005) higher with halometasone/triclosan cream (42.5%) than with the comparative preparation (22.6%). The two preparations did not differ significantly with regard to the incidence and severity of adverse effects.

[Trental forte in leg ulcer therapy. Result of a field study]. / Trental forte in der Ulcus Cruris--Therapie. Ergebnis einer Feldstudie.

In an open field study, 70 patients with leg ulcers, some existing already for a long time, were treated with Pentoxifylline in addition to the hitherto applied local therapy. The treatment usually comprised two months with a daily dosage of 800 mg up to 1200 mg (2 to 3 coated tablets Trental forte per day). More than 80% of patients with medium size ulcers could be cured by this therapy. The medicament was well tolerated.

[Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G]. / Kontrollierte klinische Studie mit den Herpes-Antigenen LUPIDON H und LUPIDON G.

Results gained in a placebo-controlled, clinical double-blind study with the Herpes antigens LUPIDON H and Lupidon G are reported. Due to treatment with LUPIDON H or LUPIDON G a cure or a more soothed course of the disease and among the indicated effects a prolongation in length of the intervals during which no relapses occurred could be observed with regard to about 80% of all the patients concerned. In opposition to the mentioned effectiveness the treatment success becoming evident after the administration of Placebo under equal test conditions was only evaluated with a rate complying to approximately 30%. The difference determined at those investigations with reference to the efficacy of LUPIDON (80%) in comparison with Placebo (30%) is statistically significant. This outcome confirms the results already observed hitherto in open clinical investigations by other examiners whose findings, too, ascribed to LUPIDON a favourable influence on Herpes simplex diseases in about 80% of treatment cases.